Mauro Vitali, head of Oncology Business Division of Daiichi Sankyo Italia Photos: Courtesy of Daiichi Sankyo. As one of the ...

“Our vision is that every Black individual diagnosed with breast cancer will feel the support of a loving community, and will ...

The indictment states that Keisuke Yoshida intentionally poisoned his 40-year-old wife, Yoko, by having her ingest methanol ...

The Japanese drugmaker has emerged as a leader in ADC, a type of cancer therapy that targets cancerous cells while sparing ...

Hiroyuki Okuzawa, President and COO at Daiichi Sankyo, says the company is working to boost production of its ...

As Daiichi Sankyo and AstraZeneca’s metastatic breast cancer drug Enhertu picks up more label expansions, the companies are targeting patients directly for the first time in messaging efforts. Daiichi ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Daiichi Sankyo submits Enhertu sNDA to Japan’s MHLF for patients with HER2 low or HER2 ultralow metastatic breast cancer: Tokyo Saturday, October 5, 2024, 10:00 Hrs [IST] Daiich ...

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY – Get Free Report) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totalling 3, ...

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's National Medical Products Administration ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer ...

Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer therapies, by pushing ahead with clinical trials of drug candidates being developed using new technology ...